>…this, and the initiative for biosimilar drugs, could produce a sea change for GTCB.<
I agree.
I’ll be updating the ReadMeFirst in the next few days with additional entries on the opportunity in the biogeneric / biosimilar / FoB / enhanced-ADCC arena. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”